Key Points
- MillerKnoll shares are trading around $20.66 ahead of the company’s fiscal first-quarter 2027 results, with investors focused on demand, margins and the outlook for office furnishings.
- Analysts expect revenue of approximately $940.9 million and EPS of $0.35, representing a year-over-year revenue decline and a significant step down from the $0.55 per share reported in the previous quarter.
- Analyst expectations remain above the current share price, with an average 12-month target of $35 based on the cited coverage, while near-term margin pressure remains a central risk.
MillerKnoll is heading into its fiscal first-quarter 2027 earnings release with investors closely watching whether demand and profitability can withstand continued cost pressure. The office furnishings manufacturer is scheduled to report before the market opens on September 22, with interim Chief Executive Jeff Stutz facing an early test of his ability to manage margins and inflationary pressures.
The shares were trading around $20.66 as of September 20. Against that backdrop, the quarterly report could provide a clearer indication of how the company is navigating softer demand and whether recent operating performance can be sustained.
Revenue and Earnings Expectations Point Lower
Analysts expect MillerKnoll to generate approximately $940.9 million in revenue during the quarter and report earnings of $0.35 per share. Both figures are expected to decline from the year-earlier period, while the projected earnings figure represents a substantial sequential decline from the $0.55 per share reported in the previous quarter.
The revenue estimate implies a decline of about 1.3% year over year. That would mark a significant change from the roughly 10.9% revenue growth recorded during the comparable quarter of the previous fiscal year, highlighting the change in operating conditions facing the company.
Previous Quarter Provided a Stronger Baseline
MillerKnoll entered the new fiscal year after reporting approximately $1.00 billion in revenue in its most recent reported quarter. Revenue increased 4.4% year over year and exceeded analyst expectations, while earnings of $0.55 per share also surpassed consensus estimates.
The prior results demonstrated that the company could continue delivering above expectations despite a challenging cost environment. The anticipated decline to $0.35 per share in the upcoming quarter, however, places greater attention on whether margin pressure is temporary or becoming a more persistent issue.
Analysts See Potential Beyond the Current Share Price
Despite the weaker near-term earnings expectations, the analyst coverage cited remains cautiously constructive. Two analysts maintain an overall Buy consensus, with an average 12-month price target of $35.00.
That target is substantially above the $20.66 share price and represents an implied difference of approximately 69%. However, the valuation gap should be viewed alongside the company’s earnings outlook rather than independently. StoneX analyst Reuben Garner has maintained a Hold rating, while expecting the company to remain broadly consistent with previous guidance assumptions even as margins face pressure.
Margins and Demand Will Be Central
The upcoming results will provide several important indicators for investors. Revenue performance will show whether demand is stabilizing, while margins will help determine how effectively MillerKnoll is managing costs. Management’s guidance will also be important because investors need to assess whether the projected earnings decline is temporary or could extend into later periods.
The contrast between lower near-term earnings expectations and the substantially higher analyst price target creates a particularly important earnings test. Stronger-than-expected demand or improving margins could change the market’s assessment, while weaker results could increase pressure on the current valuation.
What Investors May Watch Next
MillerKnoll’s fiscal first-quarter results will likely center on revenue, comparable demand trends, margins and management’s outlook for the remainder of fiscal 2027. Investors may also watch whether the company can maintain its previous guidance assumptions despite the projected decline in earnings. With the stock around $20.66 and the cited analyst target at $35, the earnings release could provide important information about whether expectations for a longer-term recovery remain supported by the company’s operating performance.
Comparison, examination, and analysis between investment houses
Leave your details, and an expert from our team will get back to you as soon as possible
* This article, in whole or in part, does not contain any promise of investment returns, nor does it constitute professional advice to make investments in any particular field.
To read more about the full disclaimer, click here- sagi habasov
- •
- 5 Min Read
- •
- ago 5 hours
SKN | Can Aytu BioPharma’s Q4 Results Clarify Its Path Beyond Continued Losses?
Aytu BioPharma is set to release its fiscal fourth-quarter 2026 results after the U.S. market closes on September 22. The
- ago 5 hours
- •
- 5 Min Read
Aytu BioPharma is set to release its fiscal fourth-quarter 2026 results after the U.S. market closes on September 22. The
- omer bar
- •
- 6 Min Read
- •
- ago 7 hours
SKN | Could AutoZone’s Earnings Report Help the Stock Recover From a 52-Week Low?
AutoZone shares are heading into the company's fiscal fourth-quarter results under pressure after the stock reached a new 52-week low
- ago 7 hours
- •
- 6 Min Read
AutoZone shares are heading into the company's fiscal fourth-quarter results under pressure after the stock reached a new 52-week low
- sagi habasov
- •
- 7 Min Read
- •
- ago 17 hours
SKN | Could Medicare GLP-1 Coverage Accelerate Eli Lilly’s Obesity Drug Growth?
Medicare Coverage Expands the GLP-1 Market Eli Lilly is seeing significant early demand from Medicare beneficiaries following the launch of
- ago 17 hours
- •
- 7 Min Read
Medicare Coverage Expands the GLP-1 Market Eli Lilly is seeing significant early demand from Medicare beneficiaries following the launch of
- omer bar
- •
- 6 Min Read
- •
- ago 22 hours
SKN | Can Novo Nordisk’s Post-Wegovy Strategy Restore Investor Confidence?
Novo’s Long-Term Strategy Fails to Calm Investors Novo Nordisk shares came under heavy pressure Monday after the Danish drugmaker unveiled
- ago 22 hours
- •
- 6 Min Read
Novo’s Long-Term Strategy Fails to Calm Investors Novo Nordisk shares came under heavy pressure Monday after the Danish drugmaker unveiled